New antileukemic agents.
Despite the tremendous progress in the treatment of childhood leukemias over the last 50 years, certain subgroups of children continue to have poor prognosis. Hence, there is a need for development of new antileukemic agents. In this review, the authors describe results of clinical trials of several new antileukemic compounds with different mechanisms of action (signal transduction inhibitors, nucleoside analogs, DNA hypomethylators, angiogenesis inhibitors, and monoclonal antibodies). Although most of these compounds are not used in pediatric leukemias, the concepts surrounding their clinical development are important to all pediatric hematologists/oncologists.
Mantadakis
Elpis
E
Pediatric Hematology/Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete, Greece.
Kalmanti
Maria
M
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D009705:Nucleosides / Q000737:chemistry / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009705:Nucleosides